These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34163136)

  • 1. Recent Advances in the Treatment of Hemophilia: A Review.
    Marchesini E; Morfini M; Valentino L
    Biologics; 2021; 15():221-235. PubMed ID: 34163136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
    Morfini M; Farrugia A
    Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M; Rapisarda CAP
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients.
    Amiral J; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):363-369. PubMed ID: 29895509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence.
    Ghosh K; Ghosh K
    Expert Rev Hematol; 2021 Aug; 14(8):721-730. PubMed ID: 34278926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia.
    Morfini M
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1359-1365. PubMed ID: 27677190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current factor IX replacement options for hemophilia B and the challenges ahead.
    Franchini M; Zaffanello M; Focosi D
    Expert Opin Pharmacother; 2023 Apr; 24(6):729-736. PubMed ID: 36963373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
    Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
    Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophilia B: current pharmacotherapy and future directions.
    Franchini M; Frattini F; Crestani S; Bonfanti C
    Expert Opin Pharmacother; 2012 Oct; 13(14):2053-63. PubMed ID: 22946758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.
    Mancuso ME; Santagostino E
    J Clin Med; 2017 Mar; 6(4):. PubMed ID: 28350322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GlycoPEGylated recombinant factor IX for hemophilia B in context.
    Santagostino E; Mancuso ME
    Drug Des Devel Ther; 2018; 12():2933-2943. PubMed ID: 30254423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for the treatment of hemophilia A and B.
    Morfini M; Zanon E
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):301-13. PubMed ID: 27547884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
    Ljung RCR
    Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition.
    Lusher JM
    Am J Med; 1991 Nov; 91(5A):30S-34S. PubMed ID: 1746594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.
    Kumar R; Dunn A; Carcao M
    Semin Thromb Hemost; 2016 Feb; 42(1):18-29. PubMed ID: 26771678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in children with hemophilia.
    Petrini P
    Paediatr Drugs; 2002; 4(7):427-37. PubMed ID: 12083971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive care for hemophilia and other inherited bleeding disorders.
    Page D
    Transfus Apher Sci; 2019 Oct; 58(5):565-568. PubMed ID: 31427262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence.
    Dargaud Y; Janbain M
    J Blood Med; 2021; 12():1031-1036. PubMed ID: 34908888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.